At the German Cancer Congress 2016, held in Berlin, Germany, from 24 to 27 February 2016, Matthias Löhr, MD, PhD, from Karolinska Institutet, Stockholm, Sweden, discusses the clinical value of next-generation sequencing for cancer management, including the accelerating trend towards evidence-based, multigene-driven personalised cancer therapeutics.
European Medical Journal
Website: http://emjreviews.com/
Twitter: https://twitter.com/EMJReviews
Facebook: https://www.facebook.com/emjreviews
Advertisement